This excerpt taken from the ARRY 8-K filed Jul 15, 2009.
Array is a Leader in the MEK Research Field
Array was an early entrant in the MEK research field and established leadership quickly. In 2003, Array partnered its first clinical candidate, the MEK inhibitor ARRY-886 (now AZD6244), with AstraZeneca as part of an exclusive collaboration centered on the discovery and development of MEK inhibitors in the field of oncology. As a result of this successful collaboration, AstraZeneca acquired worldwide rights to AZD6244 and two other compounds for use in oncology. Array retained rights to all other MEK inhibitors invented before and during the collaboration. The exclusivity of the parties relationship has recently ended, and both companies are now free to independently research, develop and commercialize small molecule MEK inhibitors in the field of oncology. In addition to ARRY-162, Array has a MEK inhibitor, ARRY-300, that has completed a Phase 1 SAD trial in healthy volunteers and will back up ARRY-162.